VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.
| Website | https://www.viantx.com |
| Employees | 5 (2 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Ophthalmology, Diabetic Retinopathy Treatment, Vision Loss Prevention, Macular Degeneration, Diabetic Retinopathy, Ocular Drug Delivery, Clinical Stage Biotech, Pharmaceutical Innovation, Eye Health, Novel Therapeutics, Drug Development, Biotechnology, Therapeutic Solutions |
| Competitors | Vertex Pharmaceuticals, CRISPR Therapeutics, Zymergen, Inc., Sangamo Therapeutics, Inc., bluebird bio, Intellia Therapeutics, Inc., Senti Biosciences, Editas Medicine, Arrowhead Pharmaceuticals, Axiogenesis +42 more (view full list) |
Looking for a particular VIAN Therapeutics employee's phone or email?
2 people are employed at VIAN Therapeutics.
VIAN Therapeutics is based in San Francisco, California.